

# Amendment Tool

v1.8 30 April 2025

For office use

QC: No

## Section 1: Project information

Short project title*:	Indigo			
IRAS project ID* (or REC reference if no IRAS project ID is available):	324034			
Sponsor amendment reference number*:	NSA_05			
Sponsor amendment date* (enter as DD/MM/YY):	23 May 2025			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	<p>In this amendment, we wish to reflect feedback from trial participants, practices and RDNs by correcting multiple typos in the questionnaire, splitting a comorbidity into two options and to add a shorter version of text used to contact eligible patients. These are minor changes (e.g., changed "counsellor" to "counselor").</p> <p>The documents affected by these changes are:</p> <ul style="list-style-type: none"> <li>- Indigo - full initial questionnaire - 2025.05.23_v1.9.docx</li> <li>- Indigo - non validated questionnaire - 2025.05.23_v1.7.docx</li> <li>- Indigo Community - Adverts (overall) - v1.4.docx</li> </ul>			
Project type (select):	<b>Specific study</b>			
	Research tissue bank			
	Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<b>Yes</b>		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	<b>NHS/HSC REC</b>			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a <b>modified amendment</b> (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		<b>No</b>	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<b>Yes</b>	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes		<b>No</b>	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		<b>No</b>	
Was the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device^ (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes		<b>No</b>	
Does the amendment make the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device^ (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes		<b>No</b>	
^ IVD medical devices are tests used on biological samples, such as tissues, blood or urine, to determine the status of a person's health. This may be a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination				
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes		<b>No</b>	
Does the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?: (e.g. the study relies upon section 251 support in England and Wales, or equivalent in Scotland to set aside the common law duty of confidentiality)	Yes		<b>No</b>	
Does the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		<b>No</b>	
Does the study involve children OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve NHS/HSC organisations prior to this amendment?:	<b>Yes</b>		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		<b>No</b>	
	England	Wales	Scotland	Northern Ireland



	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW App	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating	HSC REC	HSC Data Guardians	Prisons	National coordinating	Category:
Change 1:						(Y)				(Y)									C
Overall reviews for the amendment:																			
Full review:						N				N									
Notification only:						Y				Y									
Overall amendment type:	Non-substantial, no study-wide review required																		
Overall Category:	C																		